GL1X · GenesisL1 explorer

MolNFT v1 · #160042 · protein

Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.

6P8W · GTPase KRAS: “Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.”. X-ray diffraction, 3 ligands (GDP, O67, CA), 4 pockets (best druggability 0.67). MolNFT v1 #160042 on GenesisL1: 3D…

PDB
6P8W
Type
protein
Length
337 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
GTPase KRAS
UniProt
P01116
Ligands
GDP, O67, CA
Pockets
4 · best druggability 0.67

Structure

x-ray diffraction · 2 distinct chains · 36% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AGTPase KRASprotein16937% helix, 27% strandP01116
BGTPase KRASprotein16836% helix, 27% strandP01116

Ligands and binding sites

  • GDP · Guanosine-5'-diphosphate · ligand · 2 copies · chains A, B
  • O67 · N-(5-bromo-2-{2-oxo-2-[(1-propanoylazetidin-3-yl) amino]ethoxy}phenyl)-3-methyl-1,2-oxazole-5-carboxamide · ligand · 2 copies · chains A, B
  • CA · Calcium ion · metal · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13720.670.8146CA, GDP, O67
23300.640.8044CA, GDP, O67
31480.570.8226empty
41160.430.7828empty

Interfaces

1 interface between chains.

  • A–B · 496 Ų buried · 5 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 6P8W · Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.